ABIOMED, Inc. (NASDAQ:ABMD) Stock Position Raised by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lifted its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 160,168 shares of the medical equipment provider’s stock after acquiring an additional 1,519 shares during the quarter. Stephens Investment Management Group LLC owned 0.35% of ABIOMED worth $41,722,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Executive Wealth Management LLC lifted its holdings in shares of ABIOMED by 100.0% in the second quarter. Executive Wealth Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 50 shares in the last quarter. Piedmont Investment Advisors Inc. lifted its holdings in shares of ABIOMED by 1.4% in the first quarter. Piedmont Investment Advisors Inc. now owns 3,805 shares of the medical equipment provider’s stock valued at $1,087,000 after purchasing an additional 51 shares in the last quarter. World Asset Management Inc lifted its holdings in shares of ABIOMED by 2.0% in the second quarter. World Asset Management Inc now owns 2,922 shares of the medical equipment provider’s stock valued at $761,000 after purchasing an additional 56 shares in the last quarter. Chartwell Investment Partners LLC lifted its holdings in shares of ABIOMED by 5.0% in the first quarter. Chartwell Investment Partners LLC now owns 1,324 shares of the medical equipment provider’s stock valued at $378,000 after purchasing an additional 63 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. raised its holdings in shares of ABIOMED by 233.3% during the first quarter. Sterling Investment Advisors Ltd. now owns 100 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 70 shares in the last quarter. 86.63% of the stock is owned by institutional investors and hedge funds.

In other ABIOMED news, COO David M. Weber sold 8,095 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $206.26, for a total transaction of $1,669,674.70. Following the transaction, the chief operating officer now directly owns 132,913 shares in the company, valued at $27,414,635.38. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.40% of the stock is owned by company insiders.



Several analysts recently issued reports on the company. Zacks Investment Research lowered ABIOMED from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. SunTrust Banks reiterated a “buy” rating and set a $340.00 price objective on shares of ABIOMED in a report on Friday, May 3rd. ValuEngine lowered ABIOMED from a “hold” rating to a “sell” rating in a report on Tuesday, May 7th. William Blair reiterated a “buy” rating on shares of ABIOMED in a report on Friday, August 2nd. Finally, BidaskClub upgraded ABIOMED from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 24th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. ABIOMED currently has an average rating of “Hold” and an average target price of $316.50.

NASDAQ ABMD traded up $2.10 during trading on Thursday, hitting $192.23. 9,190 shares of the company traded hands, compared to its average volume of 796,008. ABIOMED, Inc. has a 12 month low of $181.02 and a 12 month high of $459.75. The business’s fifty day simple moving average is $244.53. The company has a market cap of $8.70 billion, a P/E ratio of 53.24, a P/E/G ratio of 1.69 and a beta of 0.31.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.01. ABIOMED had a return on equity of 19.84% and a net margin of 32.35%. The company had revenue of $207.70 million for the quarter, compared to analyst estimates of $210.96 million. During the same period last year, the company earned $1.95 earnings per share. The business’s revenue was up 15.4% compared to the same quarter last year. Research analysts predict that ABIOMED, Inc. will post 4.3 EPS for the current fiscal year.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Recommended Story: Economic Bubble

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.